Press release
Abcam and MEDx extend precision medicine strategic partnership
Cambridge, UK and Shanghai, China, 12 April : Today Abcam (AIM: ABC; NASDAQ: ABCM), a global innovator in life science reagents and tools, and MEDx Translational Medicine (MEDx), formerly QIAGEN (Suzhou) Translational Medicine Co., Ltd., a company dedicated to developing companion diagnostics and precision medicine, announced the extension of their strategic partnership to include the co-development and commercialization of key companion and in vitro diagnostic kits for MEDx to supply to the Chinese market.
- Building on existing three-year collaboration
- Focusing on co-development of companion and in vitro diagnostic kits to support demand in China
“China is embracing the arrival of precision medicine, creating unprecedented opportunities for the pharma and healthcare industry. This new collaboration expands our strong relationship with Abcam and leverages their integrated solutions to support the development of innovative diagnostic kits from target validation to clinical trial testing”
Nick Zhang
CEO of MEDx
“China is embracing the arrival of precision medicine, creating unprecedented opportunities for the pharma and healthcare industry. This new collaboration expands our strong relationship with Abcam and leverages their integrated solutions to support the development of innovative diagnostic kits from target validation to clinical trial testing”
Nick Zhang
CEO of MEDx
Under the terms of the agreement, the partners will together define target product profiles that will support the growth of precision diagnostic for selected indications in China. Abcam will provide MEDx with access to the corresponding validated specific antibodies from their pipeline and portfolio and will co-create novel binders as required. MEDx will complete the development of these into companion diagnostics and in vitro diagnostic kits for wider commercialization.
“We are looking forward to combining our end-to-end capabilities to identify and develop high-quality recombinant monoclonal antibodies with MEDx’s companion diagnostics development experience. We are excited to be partnering with MEDx and supporting their commitment to accelerate the development and marketing of precision medicine that can positively impact people’s lives across China.”
John Baker
SVP Business Development at Abcam
“We are looking forward to combining our end-to-end capabilities to identify and develop high-quality recombinant monoclonal antibodies with MEDx’s companion diagnostics development experience. We are excited to be partnering with MEDx and supporting their commitment to accelerate the development and marketing of precision medicine that can positively impact people’s lives across China.”
John Baker
SVP Business Development at Abcam
This agreement builds on an existing collaboration formed in 2018, which has delivered antibody solutions designed specifically to support the development and commercialization of several in vitro diagnostic reagents and kits by MEDx that address key targets, including NY-ESO-1, Claudin 18.2, HER2, Trop2, LAG-3 and CD73.
Registered Office:
Discovery Drive, Cambridge
Biomedical Campus,
Cambridge, CB2 0AX, UK
+44 (0) 1223 696 000
VIEW PRODUCTS
© Abcam Limited. all rights reserved.
Abcam Limited is incorporated in England and Wales, its main country of operation in the UK. Use of this website is subject to our Terms and Conditions of use and our Privacy Policy. Share price and news information on this site is updated dynamically from external data feeds.
